In today’s briefing:
- ADAP: 4Q24 Business Update
- LGVN: Alzheimer’s Treatment Gets Positive News from FDA
- MGRM: Monogram receives clearance from the FDA on its 510(k) submission for its mB s TKA System. The company can now move forward with upgrades to the system and begin the commercialization process.
ADAP: 4Q24 Business Update
- Zacks Small-Cap Research Note for Adaptimmune Therapeutics plc (ADAP)
LGVN: Alzheimer’s Treatment Gets Positive News from FDA
- Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer’s Disease.
- The company announced that it had a positive meeting with the FDA regarding the testing of Lomecel-B for the treatment of Alzheimer’s.
- The end result is the testing and approval process could be accelerated.
MGRM: Monogram receives clearance from the FDA on its 510(k) submission for its mB s TKA System. The company can now move forward with upgrades to the system and begin the commercialization process.
- Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging.
- On 5/17/25, the company received clearance from the FDA on its 510(k) submission for its mB s TKA System.
- The first live in patient surgery OUS is expected in early 2025.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
